



18 August 2014

Company Announcements Office
Australian Stock Exchange
Level 6, 20 Bridge Street
Sydney NSW 2000

Australian biotech company Anteo appoints USA based VP Scientific Affairs

- **Experienced executive in Life Sciences and IVD**
- **Joins Anteo directly from a large IVD player**
- **Bench to boardroom skills augment Anteo's commercialisation capability**

18 August 2014: Anteo Diagnostics Limited (ASX: ADO) ("Anteo") is pleased to announce the appointment of Mr Josh Soldo as VP Scientific Affairs, based in the United States.

Josh is a global scientific affairs executive with more than 15 years experience at leading In Vitro Diagnostics (IVD) companies. He has a proven track record building business relationships and selling technology in the Life Sciences and IVD markets. He is a creative and strategic thinker. Josh is well equipped to assist in the delivery winning solutions and in forging new partnerships and collaborations for Anteo.

Dr Geoff Cumming, CEO of Anteo said, "We are pleased to welcome Josh to Anteo. He is a highly regarded professional and his appointment marks an important step in the international commercialisation of our flagship product, Mix&Go, particularly in the US market. His acute knowledge of IVD companies and the regulatory marketplace will be invaluable. Strategically he provides an important link between our technical group and the demands of business development. Josh will work closely with, Tina Baumgartner, our VP Business Development currently based in Europe, to provide business solutions globally."

Josh joins Anteo from DiaSorin Inc, where he was Corporate Director of Scientific Affairs. There he oversaw product development and provided leadership to marketing and sales. In this role Josh was also required to strategically evaluate new technologies & novel biomarker collaboration and licensing opportunities.

Josh has a strong technical background and is considered a subject matter expert in solid phase chemistry and assay development. He is the principle inventor of 2 key patents in IVD, and he has authored and presented numerous publications and presentations at scientific and industry conferences.

***Anteo Diagnostics Limited* ABN 78 090 487 273**

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

Mr Soldo said: "I am very pleased to be joining the Anteo team. It is an innovative and dynamic company with a truly unique offering. I look forward to the challenges and successes ahead exploring the endless possibilities and novel applications of Anteo's cutting edge technology, and to identify and secure licensing opportunities not only within the IVD space, but also beyond diagnostics"

Anteo is an Australian biotechnology company that provides world-class solutions. Anteo uses its patented technology to develop, manufacture and commercialise proprietary surface coatings for use in healthcare, life sciences and beyond.

ENDS

For More Information Contact:

**Dr Geoff Cumming, CEO
Anteo Diagnostics Limited
Tel: +61 2 8823 3110**

***Anteo Diagnostics Limited* ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113**

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com